AIM ImmunoTech regains NYSE American listing compliance after equity deficiency resolved

AIM ImmunoTech Inc.

Received NYSE American notice on June 12, 2026 that it resolved stockholders' equity deficiencies under Sections 1003(a)(i)-(iii).
Raised ~$8.5M total through warrant exercises and stock sales: $3.5M (May 7 warrant inducement), $2.4M (May 21 placement), $2.6M (June 10 placement).
Issued over 10M shares and warrants; believes stockholders' equity now exceeds $6M minimum requirement.
".BC" indicator to be removed from trading symbol (AIM); company removed from NYSE American noncompliant list.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.